• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Progressive motor weakness in transgenic mice expressing human TDP-43.

Familial ALS patients with TDP-43 gene mutations and sporadic ALS patients share common TDP-43 neuronal pathology. To delineate mechanisms underlying TDP-43 proteinopathies, transgenic mice expressing A315T, M337V or wild type human TDP-43 were generated. Multiple TDP-43 founders developed a severe early motor phenotype that correlated with TDP-43 levels in spinal cord. Three A315T TDP-43 lines developed later onset paralysis with cytoplasmic ubiquitin inclusions, gliosis and TDP-43 redistribution and fragmentation. The WT TDP-43 mouse line with highest spinal cord expression levels remains asymptomatic, although these mice show spinal cord pathology. One WT TDP-43 line with high skeletal muscle levels of TDP-43 developed a severe progressive myopathy. Over-expression of TDP-43 in vivo is sufficient to produce progressive motor phenotypes by a toxic gain of function paradigm. Transgenic mouse lines expressing untagged mutant and wild type TDP-43 under the same promoter represent a powerful new model system for studying TDP-43 proteinopathies in vivo.

Pubmed ID: 20621187


  • Stallings NR
  • Puttaparthi K
  • Luther CM
  • Burns DK
  • Elliott JL


Neurobiology of disease

Publication Data

November 13, 2010

Associated Grants


Mesh Terms

  • Animals
  • Blotting, Western
  • DNA, Complementary
  • DNA-Binding Proteins
  • Disease Models, Animal
  • Fluorescent Antibody Technique
  • Genetic Vectors
  • Humans
  • Inclusion Bodies
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Motor Neuron Disease
  • Muscle Weakness
  • Mutation, Missense
  • Polymerase Chain Reaction
  • TDP-43 Proteinopathies